Bortezomib combination therapy in multiple myeloma.

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Bortezomib, approved in 2003, is a cornerstone in multiple myeloma (MM) treatment.
• Numerous bortezomib-based combination therapies have been developed, often by combining active agents.
• These combinations aim to improve treatment efficacy in MM.

Purpose of the Study:

• To review the efficacy and limitations of bortezomib-based combination therapies in multiple myeloma.
• To highlight specific regimens and their suitability for different clinical scenarios.
• To discuss ongoing research into novel bortezomib combinations.

Main Methods:

• Review of existing literature on bortezomib combination therapies for multiple myeloma.
• Analysis of response rates, progression-free survival, and overall survival data.
• Examination of specific regimen properties and clinical applications.

Main Results:

• Bortezomib combined with corticosteroids, alkylating agents, thalidomide, or lenalidomide achieves high response rates.
• While progression-free survival is often prolonged, an overall survival advantage is not consistently demonstrated.
• Regimens like VTD are valuable in renal failure, and VDT-PACE is useful for aggressive disease.

Conclusions:

• Bortezomib combinations offer high response rates but limited overall survival benefits in many MM cases.
• Regimen selection should consider individual patient factors and disease characteristics.
• Future research is exploring novel combinations with agents like monoclonal antibodies and pathway inhibitors.